HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast

HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast

Abstract Malignant adenomyoepithelioma (AME) of the breast is an exceptionally rare form of breast cancer, with a significant metastatic potential. Chemotherapy has been used in the management of advanced AME patients, however the majority of treatments are not effective. Recent studies report recur...

Full description

Bibliographic Details
Main Authors: Ivan Bièche, Florence Coussy, Rania El-Botty, Sophie Vacher, Sophie Château-Joubert, Ahmed Dahmani, Elodie Montaudon, Cécile Reyes, David Gentien, Fabien Reyal, Francesco Ricci, André Nicolas, Caterina Marchio, Anne Vincent-Salomon, Marick Laé, Elisabetta Marangoni
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Journal of Hematology & Oncology
Subjects:
Adenomyoepithelioma
HRAS
PDX
MEK inhibitor
Online Access:https://doi.org/10.1186/s13045-021-01158-3

Internet

https://doi.org/10.1186/s13045-021-01158-3

Similar Items